Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
indinavir
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1996
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AE02
|
| gptkbp:contraindication |
severe liver impairment
concurrent use with certain drugs |
| gptkbp:discontinued |
2019
yes |
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminatedIn |
urine
|
| gptkbp:halfLife |
1.8 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Crixivan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:sideEffect |
nausea
headache lipodystrophy kidney stones |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.
|
| gptkbp:bfsLayer |
4
|